speb/financial-data huggingface dataset:
KOLTEPATIL.NS income_statement (annual, 2023-03-31) — Interest Income: 64300000.00
KOLTEPATIL.NS income_statement (annual, 2023-03-31) — Interest Income Non Operating: 64300000.00
KOLTEPATIL.NS cash_flow (annual, 2023-03-31) — Interest Paid Cff: -554400000.00
KOLTEPATIL.NS cash_flow (annual, 2023-03-31) — Interest Received Cfi: 51700000.00
KOLTEPATIL.NS balance_sheet (annual, 2023-03-31) — Inventory: 28937600000.00
KOLTEPATIL.NS balance_sheet (annual, 2023-03-31) — Invested Capital: 14278700000.00
KOLTEPATIL.NS cash_flow (annual, 2023-03-31) — Investing Cash Flow: -592000000.00
KOLTEPATIL.NS balance_sheet (annual, 2023-03-31) — Investment Properties: 178400000.00
KOLTEPATIL.NS balance_sheet (annual, 2023-03-31) — Investmentin Financial Assets: 825200000.00
KOLTEPATIL.NS balance_sheet (annual, 2023-03-31) — Investmentsin Associatesat Cost: 409800000.00
KOLTEPATIL.NS balance_sheet (annual, 2023-03-31) — Investmentsin Joint Venturesat Cost: 19500000.00
KOLTEPATIL.NS cash_flow (annual, 2023-03-31) — Issuance Of Debt: 2766900000.00
KOLTEPATIL.NS balance_sheet (annual, 2023-03-31) — Land And Improvements: 55500000.00
KOLTEPATIL.NS balance_sheet (annual, 2023-03-31) — Long Term Capital Lease Obligation: 134000000.00
KOLTEPATIL.NS balance_sheet (annual, 2023-03-31) — Long Term Debt: 3492000000.00
KOLTEPATIL.NS balance_sheet (annual, 2023-03-31) — Long Term Debt And Capital Lease Obligation: 3626000000.00
KOLTEPATIL.NS cash_flow (annual, 2023-03-31) — Long Term Debt Issuance: 2765500000.00
KOLTEPATIL.NS cash_flow (annual, 2023-03-31) — Long Term Debt Payments: -2567700000.00
KOLTEPATIL.NS balance_sheet (annual, 2023-03-31) — Long Term Equity Investment: 429300000.00
KOLTEPATIL.NS balance_sheet (annual, 2023-03-31) — Long Term Provisions: 494900000.00
KOLTEPATIL.NS balance_sheet (annual, 2023-03-31) — Machinery Furniture Equipment: 1065500000.00
KOLTEPATIL.NS balance_sheet (annual, 2023-03-31) — Minority Interest: 85600000.00
KOLTEPATIL.NS income_statement (annual, 2023-03-31) — Minority Interests: -93900000.00
KOLTEPATIL.NS cash_flow (annual, 2023-03-31) — Net Business Purchase And Sale: -602200000.00
KOLTEPATIL.NS balance_sheet (annual, 2023-03-31) — Net Debt: 3157900000.00
KOLTEPATIL.NS income_statement (annual, 2023-03-31) — Net Income: 1040600000.00
KOLTEPATIL.NS income_statement (annual, 2023-03-31) — Net Income Common Stockholders: 1040600000.00
KOLTEPATIL.NS income_statement (annual, 2023-03-31) — Net Income Continuous Operations: 1134500000.00
KOLTEPATIL.NS income_statement (annual, 2023-03-31) — Net Income From Continuing And Discontinued Operation: 1040600000.00
KOLTEPATIL.NS income_statement (annual, 2023-03-31) — Net Income From Continuing Operation Net Minority Interest: 1040600000.00
KOLTEPATIL.NS cash_flow (annual, 2023-03-31) — Net Income From Continuing Operations: 1696300000.00
KOLTEPATIL.NS income_statement (annual, 2023-03-31) — Net Income Including Noncontrolling Interests: 1134500000.00
KOLTEPATIL.NS income_statement (annual, 2023-03-31) — Net Interest Income: -342400000.00
KOLTEPATIL.NS cash_flow (annual, 2023-03-31) — Net Investment Purchase And Sale: 33700000.00
KOLTEPATIL.NS cash_flow (annual, 2023-03-31) — Net Issuance Payments Of Debt: 199200000.00
KOLTEPATIL.NS cash_flow (annual, 2023-03-31) — Net Long Term Debt Issuance: 197800000.00
KOLTEPATIL.NS income_statement (annual, 2023-03-31) — Net Non Operating Interest Income Expense: -342400000.00
KOLTEPATIL.NS cash_flow (annual, 2023-03-31) — Net Other Financing Charges: -32900000.00
KOLTEPATIL.NS cash_flow (annual, 2023-03-31) — Net Other Investing Changes: 106300000.00
KOLTEPATIL.NS balance_sheet (annual, 2023-03-31) — Net PPE: 771900000.00
KOLTEPATIL.NS cash_flow (annual, 2023-03-31) — Net PPE Purchase And Sale: -183300000.00
KOLTEPATIL.NS cash_flow (annual, 2023-03-31) — Net Short Term Debt Issuance: 1400000.00
KOLTEPATIL.NS balance_sheet (annual, 2023-03-31) — Net Tangible Assets: 8620700000.00
KOLTEPATIL.NS balance_sheet (annual, 2023-03-31) — Non Current Deferred Revenue: 35900000.00
KOLTEPATIL.NS balance_sheet (annual, 2023-03-31) — Non Current Deferred Taxes Assets: 1650000000.00
KOLTEPATIL.NS balance_sheet (annual, 2023-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 92200000.00
KOLTEPATIL.NS balance_sheet (annual, 2023-03-31) — Non Current Prepaid Assets: 1667500000.00
KOLTEPATIL.NS income_statement (annual, 2023-03-31) — Normalized EBITDA: 2082800000.00
KOLTEPATIL.NS income_statement (annual, 2023-03-31) — Normalized Income: 973308876.20
KOLTEPATIL.NS cash_flow (annual, 2023-03-31) — Operating Cash Flow: 1976900000.00
KOLTEPATIL.NS income_statement (annual, 2023-03-31) — Operating Income: 1815200000.00
KOLTEPATIL.NS income_statement (annual, 2023-03-31) — Operating Revenue: 14881700000.00
KOLTEPATIL.NS balance_sheet (annual, 2023-03-31) — Ordinary Shares Number: 76004409.00
KOLTEPATIL.NS cash_flow (annual, 2023-03-31) — Other Cash Adjustment Outside Changein Cash: 3200000.00
KOLTEPATIL.NS balance_sheet (annual, 2023-03-31) — Other Current Assets: 1708200000.00
KOLTEPATIL.NS balance_sheet (annual, 2023-03-31) — Other Current Liabilities: 20391700000.00
KOLTEPATIL.NS balance_sheet (annual, 2023-03-31) — Other Equity Interest: 8103500000.00
KOLTEPATIL.NS balance_sheet (annual, 2023-03-31) — Other Intangible Assets: 8200000.00
KOLTEPATIL.NS cash_flow (annual, 2023-03-31) — Other Non Cash Items: 419700000.00
KOLTEPATIL.NS balance_sheet (annual, 2023-03-31) — Other Non Current Assets: 1466900000.00
KOLTEPATIL.NS balance_sheet (annual, 2023-03-31) — Other Non Current Liabilities: 35900000.00
KOLTEPATIL.NS income_statement (annual, 2023-03-31) — Other Non Operating Income Expenses: 122000000.00
KOLTEPATIL.NS income_statement (annual, 2023-03-31) — Other Operating Expenses: 559000000.00
KOLTEPATIL.NS balance_sheet (annual, 2023-03-31) — Other Payable: 242400000.00
KOLTEPATIL.NS balance_sheet (annual, 2023-03-31) — Other Properties: 172900000.00
KOLTEPATIL.NS balance_sheet (annual, 2023-03-31) — Other Receivables: 112600000.00
KOLTEPATIL.NS balance_sheet (annual, 2023-03-31) — Other Short Term Investments: 1413300000.00
KOLTEPATIL.NS income_statement (annual, 2023-03-31) — Other Special Charges: -1500000.00
KOLTEPATIL.NS income_statement (annual, 2023-03-31) — Otherunder Preferred Stock Dividend: 0.00
KOLTEPATIL.NS balance_sheet (annual, 2023-03-31) — Payables: 3845600000.00
KOLTEPATIL.NS balance_sheet (annual, 2023-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 122200000.00
KOLTEPATIL.NS balance_sheet (annual, 2023-03-31) — Prepaid Assets: 1706800000.00
KOLTEPATIL.NS income_statement (annual, 2023-03-31) — Pretax Income: 1680900000.00
KOLTEPATIL.NS balance_sheet (annual, 2023-03-31) — Properties: 0.00
KOLTEPATIL.NS cash_flow (annual, 2023-03-31) — Provisionand Write Offof Assets: 38500000.00
KOLTEPATIL.NS cash_flow (annual, 2023-03-31) — Purchase Of Business: -602200000.00
KOLTEPATIL.NS cash_flow (annual, 2023-03-31) — Purchase Of Investment: -85500000.00
KOLTEPATIL.NS cash_flow (annual, 2023-03-31) — Purchase Of PPE: -184800000.00
KOLTEPATIL.NS balance_sheet (annual, 2023-03-31) — Raw Materials: 353900000.00
KOLTEPATIL.NS income_statement (annual, 2023-03-31) — Reconciled Cost Of Revenue: 10892300000.00
KOLTEPATIL.NS income_statement (annual, 2023-03-31) — Reconciled Depreciation: 115600000.00
KOLTEPATIL.NS income_statement (annual, 2023-03-31) — Rent And Landing Fees: 18700000.00
KOLTEPATIL.NS income_statement (annual, 2023-03-31) — Rent Expense Supplemental: 18700000.00
KOLTEPATIL.NS cash_flow (annual, 2023-03-31) — Repayment Of Debt: -2567700000.00
KOLTEPATIL.NS balance_sheet (annual, 2023-03-31) — Restricted Cash: 803000000.00
KOLTEPATIL.NS balance_sheet (annual, 2023-03-31) — Retained Earnings: 5941000000.00
KOLTEPATIL.NS cash_flow (annual, 2023-03-31) — Sale Of Business: 0.00
KOLTEPATIL.NS cash_flow (annual, 2023-03-31) — Sale Of Investment: 119200000.00
KOLTEPATIL.NS cash_flow (annual, 2023-03-31) — Sale Of PPE: 1500000.00
KOLTEPATIL.NS income_statement (annual, 2023-03-31) — Selling And Marketing Expense: 444900000.00
KOLTEPATIL.NS income_statement (annual, 2023-03-31) — Selling General And Administration: 626000000.00
KOLTEPATIL.NS balance_sheet (annual, 2023-03-31) — Share Issued: 76004409.00
KOLTEPATIL.NS cash_flow (annual, 2023-03-31) — Short Term Debt Issuance: 1400000.00
KOLTEPATIL.NS income_statement (annual, 2023-03-31) — Special Income Charges: 1500000.00
KOLTEPATIL.NS cash_flow (annual, 2023-03-31) — Stock Based Compensation: 0.00
KOLTEPATIL.NS balance_sheet (annual, 2023-03-31) — Stockholders Equity: 8863500000.00
KOLTEPATIL.NS balance_sheet (annual, 2023-03-31) — Tangible Book Value: 8620700000.00
KOLTEPATIL.NS income_statement (annual, 2023-03-31) — Tax Effect Of Unusual Items: 32408876.20
KOLTEPATIL.NS income_statement (annual, 2023-03-31) — Tax Provision: 546400000.00
KOLTEPATIL.NS income_statement (annual, 2023-03-31) — Tax Rate For Calcs: 0.33
KOLTEPATIL.NS cash_flow (annual, 2023-03-31) — Taxes Refund Paid: -563300000.00
KOLTEPATIL.NS balance_sheet (annual, 2023-03-31) — Total Assets: 40257000000.00
KOLTEPATIL.NS balance_sheet (annual, 2023-03-31) — Total Capitalization: 12355500000.00
KOLTEPATIL.NS balance_sheet (annual, 2023-03-31) — Total Debt: 5614800000.00
KOLTEPATIL.NS balance_sheet (annual, 2023-03-31) — Total Equity Gross Minority Interest: 8949100000.00
KOLTEPATIL.NS income_statement (annual, 2023-03-31) — Total Expenses: 13066500000.00
KOLTEPATIL.NS balance_sheet (annual, 2023-03-31) — Total Liabilities Net Minority Interest: 31307900000.00
KOLTEPATIL.NS balance_sheet (annual, 2023-03-31) — Total Non Current Assets: 5667200000.00
KOLTEPATIL.NS balance_sheet (annual, 2023-03-31) — Total Non Current Liabilities Net Minority Interest: 4669300000.00
KOLTEPATIL.NS income_statement (annual, 2023-03-31) — Total Other Finance Cost: 20700000.00
KOLTEPATIL.NS balance_sheet (annual, 2023-03-31) — Total Tax Payable: 115100000.00
KOLTEPATIL.NS income_statement (annual, 2023-03-31) — Total Unusual Items: 99700000.00
KOLTEPATIL.NS income_statement (annual, 2023-03-31) — Total Unusual Items Excluding Goodwill: 99700000.00
KOLTEPATIL.NS balance_sheet (annual, 2023-03-31) — Tradeand Other Payables Non Current: 19200000.00
KOLTEPATIL.NS balance_sheet (annual, 2023-03-31) — Working Capital: 7951200000.00
KOLTEPATIL.NS income_statement (annual, 2024-03-31) — +Operating Expense: 2574600000.00
KOLTEPATIL.NS income_statement (annual, 2024-03-31) — +Total Revenue: 13714800000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Accounts Payable: 5737500000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Accounts Receivable: 556700000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Accumulated Depreciation: -797900000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Additional Paid In Capital: 3393500000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Allowance For Doubtful Accounts Receivable: -84900000.00
KOLTEPATIL.NS income_statement (annual, 2024-03-31) — Amortization: 7000000.00
KOLTEPATIL.NS cash_flow (annual, 2024-03-31) — Amortization Cash Flow: 7000000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Available For Sale Securities: 88400000.00
KOLTEPATIL.NS income_statement (annual, 2024-03-31) — Basic Average Shares: 76000000.00
KOLTEPATIL.NS income_statement (annual, 2024-03-31) — Basic EPS: -9.12
KOLTEPATIL.NS cash_flow (annual, 2024-03-31) — Beginning Cash Position: 2257300000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Buildings And Improvements: 62600000.00
KOLTEPATIL.NS cash_flow (annual, 2024-03-31) — Capital Expenditure: -431200000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Capital Lease Obligations: 381800000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Capital Stock: 760000000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Cash And Cash Equivalents: 2997600000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Cash Cash Equivalents And Short Term Investments: 4628600000.00
KOLTEPATIL.NS cash_flow (annual, 2024-03-31) — Cash Dividends Paid: -304000000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Cash Equivalents: 397500000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Cash Financial: 2600100000.00
KOLTEPATIL.NS cash_flow (annual, 2024-03-31) — Change In Inventory: -4689900000.00
KOLTEPATIL.NS cash_flow (annual, 2024-03-31) — Change In Other Current Assets: -1343000000.00
KOLTEPATIL.NS cash_flow (annual, 2024-03-31) — Change In Other Current Liabilities: 3150100000.00
KOLTEPATIL.NS cash_flow (annual, 2024-03-31) — Change In Payable: 1998700000.00
KOLTEPATIL.NS cash_flow (annual, 2024-03-31) — Change In Receivables: -234500000.00
KOLTEPATIL.NS cash_flow (annual, 2024-03-31) — Change In Working Capital: -1449800000.00
KOLTEPATIL.NS cash_flow (annual, 2024-03-31) — Changes In Cash: 740300000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Common Stock: 760000000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Common Stock Equity: 7528800000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Construction In Progress: 0.00
KOLTEPATIL.NS income_statement (annual, 2024-03-31) — Cost Of Revenue: 10760200000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Current Assets: 42703900000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Current Capital Lease Obligation: 81500000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Current Debt: 8585800000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Current Debt And Capital Lease Obligation: 8667300000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Current Liabilities: 38326800000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Current Provisions: 151800000.00
KOLTEPATIL.NS cash_flow (annual, 2024-03-31) — Depreciation: 134900000.00
KOLTEPATIL.NS cash_flow (annual, 2024-03-31) — Depreciation And Amortization: 141900000.00
KOLTEPATIL.NS income_statement (annual, 2024-03-31) — Depreciation And Amortization In Income Statement: 141900000.00
KOLTEPATIL.NS income_statement (annual, 2024-03-31) — Depreciation Income Statement: 134900000.00
KOLTEPATIL.NS income_statement (annual, 2024-03-31) — Diluted Average Shares: 76000000.00
KOLTEPATIL.NS income_statement (annual, 2024-03-31) — Diluted EPS: -9.12
KOLTEPATIL.NS income_statement (annual, 2024-03-31) — Diluted NI Availto Com Stockholders: -693500000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Dividends Payable: 1700000.00
KOLTEPATIL.NS cash_flow (annual, 2024-03-31) — Dividends Received Cfi: 0.00
KOLTEPATIL.NS income_statement (annual, 2024-03-31) — EBIT: 203700000.00
KOLTEPATIL.NS income_statement (annual, 2024-03-31) — EBITDA: 345600000.00
KOLTEPATIL.NS cash_flow (annual, 2024-03-31) — End Cash Position: 2997600000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 1400000.00
KOLTEPATIL.NS cash_flow (annual, 2024-03-31) — Financing Cash Flow: 3188400000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Finished Goods: 34246300000.00
KOLTEPATIL.NS cash_flow (annual, 2024-03-31) — Free Cash Flow: -1541300000.00
KOLTEPATIL.NS cash_flow (annual, 2024-03-31) — Gain Loss On Investment Securities: -18300000.00
KOLTEPATIL.NS cash_flow (annual, 2024-03-31) — Gain Loss On Sale Of PPE: -3300000.00
KOLTEPATIL.NS income_statement (annual, 2024-03-31) — General And Administrative Expense: 236100000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Goodwill: 0.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Goodwill And Other Intangible Assets: 5900000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Gross Accounts Receivable: 641600000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Gross PPE: 1978700000.00
KOLTEPATIL.NS income_statement (annual, 2024-03-31) — Gross Profit: 2954600000.00
KOLTEPATIL.NS income_statement (annual, 2024-03-31) — Interest Expense: 912400000.00
KOLTEPATIL.NS income_statement (annual, 2024-03-31) — Interest Expense Non Operating: 912400000.00
KOLTEPATIL.NS income_statement (annual, 2024-03-31) — Interest Income: 76000000.00
KOLTEPATIL.NS income_statement (annual, 2024-03-31) — Interest Income Non Operating: 76000000.00
KOLTEPATIL.NS cash_flow (annual, 2024-03-31) — Interest Paid Cff: -1106600000.00
KOLTEPATIL.NS cash_flow (annual, 2024-03-31) — Interest Received Cfi: 80600000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Inventory: 34685200000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Invested Capital: 18314700000.00
KOLTEPATIL.NS cash_flow (annual, 2024-03-31) — Investing Cash Flow: -1338000000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Investment Properties: 173700000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Investmentin Financial Assets: 1400000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Investmentsin Associatesat Cost: 258900000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Investmentsin Joint Venturesat Cost: 56500000.00
KOLTEPATIL.NS cash_flow (annual, 2024-03-31) — Issuance Of Debt: 7678800000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Land And Improvements: 55500000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Long Term Capital Lease Obligation: 300300000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Long Term Debt: 2200100000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Long Term Debt And Capital Lease Obligation: 2500400000.00
KOLTEPATIL.NS cash_flow (annual, 2024-03-31) — Long Term Debt Issuance: 7678800000.00
KOLTEPATIL.NS cash_flow (annual, 2024-03-31) — Long Term Debt Payments: -3003000000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Long Term Equity Investment: 315400000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Long Term Provisions: 134300000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Machinery Furniture Equipment: 1554000000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Minority Interest: 16400000.00
KOLTEPATIL.NS income_statement (annual, 2024-03-31) — Minority Interests: -18700000.00
KOLTEPATIL.NS cash_flow (annual, 2024-03-31) — Net Business Purchase And Sale: -290800000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Net Debt: 7788300000.00
KOLTEPATIL.NS income_statement (annual, 2024-03-31) — Net Income: -693500000.00
KOLTEPATIL.NS income_statement (annual, 2024-03-31) — Net Income Common Stockholders: -693500000.00
KOLTEPATIL.NS income_statement (annual, 2024-03-31) — Net Income Continuous Operations: -674800000.00
KOLTEPATIL.NS income_statement (annual, 2024-03-31) — Net Income From Continuing And Discontinued Operation: -693500000.00
KOLTEPATIL.NS income_statement (annual, 2024-03-31) — Net Income From Continuing Operation Net Minority Interest: -693500000.00
KOLTEPATIL.NS cash_flow (annual, 2024-03-31) — Net Income From Continuing Operations: -611100000.00
KOLTEPATIL.NS income_statement (annual, 2024-03-31) — Net Income Including Noncontrolling Interests: -674800000.00
KOLTEPATIL.NS income_statement (annual, 2024-03-31) — Net Interest Income: -902600000.00
KOLTEPATIL.NS cash_flow (annual, 2024-03-31) — Net Investment Purchase And Sale: -1108400000.00
KOLTEPATIL.NS cash_flow (annual, 2024-03-31) — Net Issuance Payments Of Debt: 4675800000.00
KOLTEPATIL.NS cash_flow (annual, 2024-03-31) — Net Long Term Debt Issuance: 4675800000.00
KOLTEPATIL.NS income_statement (annual, 2024-03-31) — Net Non Operating Interest Income Expense: -902600000.00
KOLTEPATIL.NS cash_flow (annual, 2024-03-31) — Net Other Investing Changes: 400000000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Net PPE: 1180800000.00
KOLTEPATIL.NS cash_flow (annual, 2024-03-31) — Net PPE Purchase And Sale: -419400000.00
KOLTEPATIL.NS cash_flow (annual, 2024-03-31) — Net Short Term Debt Issuance: 0.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Net Tangible Assets: 7522900000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Non Current Deferred Revenue: 0.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Non Current Deferred Taxes Assets: 1839500000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 134300000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Non Current Prepaid Assets: 2405000000.00
KOLTEPATIL.NS income_statement (annual, 2024-03-31) — Normalized EBITDA: 334000000.00
KOLTEPATIL.NS income_statement (annual, 2024-03-31) — Normalized Income: -246566995.91
KOLTEPATIL.NS cash_flow (annual, 2024-03-31) — Operating Cash Flow: -1110100000.00
KOLTEPATIL.NS income_statement (annual, 2024-03-31) — Operating Income: 380000000.00
KOLTEPATIL.NS income_statement (annual, 2024-03-31) — Operating Revenue: 13714800000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Ordinary Shares Number: 76004409.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Other Current Assets: 26300000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Other Current Liabilities: 53300000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Other Equity Interest: 100000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Other Intangible Assets: 5900000.00
KOLTEPATIL.NS cash_flow (annual, 2024-03-31) — Other Non Cash Items: 888000000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Other Non Current Assets: 200000.00
KOLTEPATIL.NS income_statement (annual, 2024-03-31) — Other Non Operating Income Expenses: 123200000.00
KOLTEPATIL.NS income_statement (annual, 2024-03-31) — Other Operating Expenses: 714800000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Other Payable: 367900000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Other Properties: 306600000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Other Receivables: 36900000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Other Short Term Investments: 1631000000.00
KOLTEPATIL.NS income_statement (annual, 2024-03-31) — Other Special Charges: -3300000.00
KOLTEPATIL.NS income_statement (annual, 2024-03-31) — Otherunder Preferred Stock Dividend: 0.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Payables: 6148100000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 151800000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Prepaid Assets: 2367200000.00
KOLTEPATIL.NS income_statement (annual, 2024-03-31) — Pretax Income: -708700000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Properties: 0.00
KOLTEPATIL.NS cash_flow (annual, 2024-03-31) — Provisionand Write Offof Assets: 61400000.00
KOLTEPATIL.NS cash_flow (annual, 2024-03-31) — Purchase Of Business: -383500000.00
KOLTEPATIL.NS cash_flow (annual, 2024-03-31) — Purchase Of Investment: -1451400000.00
KOLTEPATIL.NS cash_flow (annual, 2024-03-31) — Purchase Of PPE: -431200000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Raw Materials: 438900000.00
KOLTEPATIL.NS income_statement (annual, 2024-03-31) — Reconciled Cost Of Revenue: 10760200000.00
KOLTEPATIL.NS income_statement (annual, 2024-03-31) — Reconciled Depreciation: 141900000.00
KOLTEPATIL.NS income_statement (annual, 2024-03-31) — Rent And Landing Fees: 22200000.00
KOLTEPATIL.NS income_statement (annual, 2024-03-31) — Rent Expense Supplemental: 22200000.00
KOLTEPATIL.NS cash_flow (annual, 2024-03-31) — Repayment Of Debt: -3003000000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Restricted Cash: 403000000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Retained Earnings: 5159000000.00
KOLTEPATIL.NS cash_flow (annual, 2024-03-31) — Sale Of Business: 92700000.00
KOLTEPATIL.NS cash_flow (annual, 2024-03-31) — Sale Of Investment: 343000000.00
KOLTEPATIL.NS cash_flow (annual, 2024-03-31) — Sale Of PPE: 11800000.00
KOLTEPATIL.NS income_statement (annual, 2024-03-31) — Selling And Marketing Expense: 487900000.00
KOLTEPATIL.NS income_statement (annual, 2024-03-31) — Selling General And Administration: 724000000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Share Issued: 76004409.00
KOLTEPATIL.NS cash_flow (annual, 2024-03-31) — Short Term Debt Issuance: 0.00
KOLTEPATIL.NS income_statement (annual, 2024-03-31) — Special Income Charges: -231300000.00
KOLTEPATIL.NS cash_flow (annual, 2024-03-31) — Stock Based Compensation: 0.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Stockholders Equity: 7528800000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Tangible Book Value: 7522900000.00
KOLTEPATIL.NS income_statement (annual, 2024-03-31) — Tax Effect Of Unusual Items: -10666995.91
KOLTEPATIL.NS income_statement (annual, 2024-03-31) — Tax Provision: -33900000.00
KOLTEPATIL.NS income_statement (annual, 2024-03-31) — Tax Rate For Calcs: 0.05
KOLTEPATIL.NS cash_flow (annual, 2024-03-31) — Taxes Refund Paid: -353500000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Total Assets: 49409700000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Total Capitalization: 9728900000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Total Debt: 11167700000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Total Equity Gross Minority Interest: 7545200000.00
KOLTEPATIL.NS income_statement (annual, 2024-03-31) — Total Expenses: 13334800000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Total Liabilities Net Minority Interest: 41864500000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Total Non Current Assets: 6705800000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Total Non Current Liabilities Net Minority Interest: 3537700000.00
KOLTEPATIL.NS income_statement (annual, 2024-03-31) — Total Other Finance Cost: 66200000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Total Tax Payable: 41000000.00
KOLTEPATIL.NS income_statement (annual, 2024-03-31) — Total Unusual Items: 11600000.00
KOLTEPATIL.NS income_statement (annual, 2024-03-31) — Total Unusual Items Excluding Goodwill: -223000000.00
KOLTEPATIL.NS balance_sheet (annual, 2024-03-31) — Working Capital: 4377100000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2024-09-30) — Accounts Payable: 5060800000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2024-09-30) — Accounts Receivable: 891500000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2024-09-30) — Available For Sale Securities: 1388500000.00
KOLTEPATIL.NS income_statement (quarterly, 2024-09-30) — Basic Average Shares: 76093750.00
KOLTEPATIL.NS income_statement (quarterly, 2024-09-30) — Basic EPS: 1.28
KOLTEPATIL.NS balance_sheet (quarterly, 2024-09-30) — Capital Lease Obligations: 343500000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2024-09-30) — Capital Stock: 760000000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2024-09-30) — Cash And Cash Equivalents: 3486900000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2024-09-30) — Cash Cash Equivalents And Short Term Investments: 5728000000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2024-09-30) — Common Stock: 760000000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2024-09-30) — Common Stock Equity: 7195300000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2024-09-30) — Current Assets: 45645500000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2024-09-30) — Current Capital Lease Obligation: 89800000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2024-09-30) — Current Debt: 12160900000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2024-09-30) — Current Debt And Capital Lease Obligation: 12250700000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2024-09-30) — Current Liabilities: 44284200000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2024-09-30) — Current Provisions: 185700000.00
KOLTEPATIL.NS income_statement (quarterly, 2024-09-30) — Diluted Average Shares: 76093750.00
KOLTEPATIL.NS income_statement (quarterly, 2024-09-30) — Diluted EPS: 1.28
KOLTEPATIL.NS balance_sheet (quarterly, 2024-09-30) — Goodwill And Other Intangible Assets: 5100000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2024-09-30) — Gross PPE: 1308500000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2024-09-30) — Inventory: 35924700000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2024-09-30) — Invested Capital: 19358300000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2024-09-30) — Investment Properties: 171400000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2024-09-30) — Investmentin Financial Assets: 1388500000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2024-09-30) — Long Term Capital Lease Obligation: 253700000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2024-09-30) — Long Term Debt: 2100000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2024-09-30) — Long Term Debt And Capital Lease Obligation: 255800000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2024-09-30) — Long Term Provisions: 126500000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2024-09-30) — Minority Interest: 14000000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2024-09-30) — Net Debt: 8676100000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2024-09-30) — Net PPE: 1308500000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2024-09-30) — Net Tangible Assets: 7190200000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2024-09-30) — Non Current Deferred Taxes Assets: 1914600000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2024-09-30) — Ordinary Shares Number: 76004409.00
KOLTEPATIL.NS balance_sheet (quarterly, 2024-09-30) — Other Current Assets: 3101300000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2024-09-30) — Other Current Liabilities: 26364900000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2024-09-30) — Other Equity Interest: 6435300000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2024-09-30) — Other Non Current Assets: 1915000000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2024-09-30) — Other Properties: 1308500000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2024-09-30) — Other Short Term Investments: 2241100000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2024-09-30) — Payables: 5188200000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2024-09-30) — Share Issued: 76004409.00
KOLTEPATIL.NS income_statement (quarterly, 2024-09-30) — Special Income Charges: 0.00
KOLTEPATIL.NS balance_sheet (quarterly, 2024-09-30) — Stockholders Equity: 7195300000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2024-09-30) — Tangible Book Value: 7190200000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2024-09-30) — Total Assets: 52852200000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2024-09-30) — Total Capitalization: 7197400000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2024-09-30) — Total Debt: 12506500000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2024-09-30) — Total Equity Gross Minority Interest: 7209300000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2024-09-30) — Total Liabilities Net Minority Interest: 45642900000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2024-09-30) — Total Non Current Assets: 7206700000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2024-09-30) — Total Non Current Liabilities Net Minority Interest: 1358700000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2024-09-30) — Total Tax Payable: 127400000.00
KOLTEPATIL.NS income_statement (quarterly, 2024-09-30) — Total Unusual Items: 0.00
KOLTEPATIL.NS income_statement (quarterly, 2024-09-30) — Total Unusual Items Excluding Goodwill: 0.00
KOLTEPATIL.NS balance_sheet (quarterly, 2024-09-30) — Working Capital: 1361300000.00
KOLTEPATIL.NS income_statement (quarterly, 2024-12-31) — +Operating Expense: 636700000.00
KOLTEPATIL.NS income_statement (quarterly, 2024-12-31) — +Total Revenue: 3496700000.00
KOLTEPATIL.NS income_statement (quarterly, 2024-12-31) — Basic Average Shares: 75975976.00
KOLTEPATIL.NS income_statement (quarterly, 2024-12-31) — Basic EPS: 3.33
KOLTEPATIL.NS income_statement (quarterly, 2024-12-31) — Cost Of Revenue: 2638500000.00
KOLTEPATIL.NS income_statement (quarterly, 2024-12-31) — Depreciation And Amortization In Income Statement: 34000000.00
KOLTEPATIL.NS income_statement (quarterly, 2024-12-31) — Depreciation Income Statement: 34000000.00
KOLTEPATIL.NS income_statement (quarterly, 2024-12-31) — Diluted Average Shares: 75975976.00
KOLTEPATIL.NS income_statement (quarterly, 2024-12-31) — Diluted EPS: 3.33
KOLTEPATIL.NS income_statement (quarterly, 2024-12-31) — Diluted NI Availto Com Stockholders: 253000000.00
KOLTEPATIL.NS income_statement (quarterly, 2024-12-31) — EBIT: 419800000.00
KOLTEPATIL.NS income_statement (quarterly, 2024-12-31) — EBITDA: 453800000.00
KOLTEPATIL.NS income_statement (quarterly, 2024-12-31) — Gross Profit: 858200000.00
KOLTEPATIL.NS income_statement (quarterly, 2024-12-31) — Interest Expense: 60800000.00
KOLTEPATIL.NS income_statement (quarterly, 2024-12-31) — Interest Expense Non Operating: 60800000.00
KOLTEPATIL.NS income_statement (quarterly, 2024-12-31) — Minority Interests: -10300000.00
KOLTEPATIL.NS income_statement (quarterly, 2024-12-31) — Net Income: 253000000.00
KOLTEPATIL.NS income_statement (quarterly, 2024-12-31) — Net Income Common Stockholders: 253000000.00
KOLTEPATIL.NS income_statement (quarterly, 2024-12-31) — Net Income Continuous Operations: 263300000.00
KOLTEPATIL.NS income_statement (quarterly, 2024-12-31) — Net Income From Continuing And Discontinued Operation: 253000000.00
KOLTEPATIL.NS income_statement (quarterly, 2024-12-31) — Net Income From Continuing Operation Net Minority Interest: 253000000.00
KOLTEPATIL.NS income_statement (quarterly, 2024-12-31) — Net Income Including Noncontrolling Interests: 263300000.00
KOLTEPATIL.NS income_statement (quarterly, 2024-12-31) — Net Interest Income: -60800000.00
KOLTEPATIL.NS income_statement (quarterly, 2024-12-31) — Net Non Operating Interest Income Expense: -60800000.00
KOLTEPATIL.NS income_statement (quarterly, 2024-12-31) — Normalized EBITDA: 453800000.00
KOLTEPATIL.NS income_statement (quarterly, 2024-12-31) — Normalized Income: 253000000.00
KOLTEPATIL.NS income_statement (quarterly, 2024-12-31) — Operating Income: 221500000.00
KOLTEPATIL.NS income_statement (quarterly, 2024-12-31) — Operating Revenue: 3496700000.00
KOLTEPATIL.NS income_statement (quarterly, 2024-12-31) — Other Non Operating Income Expenses: 196100000.00
KOLTEPATIL.NS income_statement (quarterly, 2024-12-31) — Other Operating Expenses: 373000000.00
KOLTEPATIL.NS income_statement (quarterly, 2024-12-31) — Otherunder Preferred Stock Dividend: 0.00
KOLTEPATIL.NS income_statement (quarterly, 2024-12-31) — Pretax Income: 359000000.00
KOLTEPATIL.NS income_statement (quarterly, 2024-12-31) — Reconciled Cost Of Revenue: 2638500000.00
KOLTEPATIL.NS income_statement (quarterly, 2024-12-31) — Reconciled Depreciation: 34000000.00
KOLTEPATIL.NS income_statement (quarterly, 2024-12-31) — Special Income Charges: 0.00
KOLTEPATIL.NS income_statement (quarterly, 2024-12-31) — Tax Effect Of Unusual Items: 0.00
KOLTEPATIL.NS income_statement (quarterly, 2024-12-31) — Tax Provision: 95700000.00
KOLTEPATIL.NS income_statement (quarterly, 2024-12-31) — Tax Rate For Calcs: 0.27
KOLTEPATIL.NS income_statement (quarterly, 2024-12-31) — Total Expenses: 3275200000.00
KOLTEPATIL.NS income_statement (quarterly, 2024-12-31) — Total Unusual Items: 0.00
KOLTEPATIL.NS income_statement (quarterly, 2024-12-31) — Total Unusual Items Excluding Goodwill: 0.00
KOLTEPATIL.NS income_statement (annual, 2025-03-31) — +Operating Expense: 2550200000.00
KOLTEPATIL.NS income_statement (quarterly, 2025-03-31) — +Operating Expense: 735200000.00
KOLTEPATIL.NS income_statement (annual, 2025-03-31) — +Total Revenue: 17173800000.00
KOLTEPATIL.NS income_statement (quarterly, 2025-03-31) — +Total Revenue: 7186700000.00
KOLTEPATIL.NS balance_sheet (annual, 2025-03-31) — Accounts Payable: 5432600000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2025-03-31) — Accounts Payable: 5432600000.00
KOLTEPATIL.NS balance_sheet (annual, 2025-03-31) — Accounts Receivable: 621300000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2025-03-31) — Accounts Receivable: 621300000.00
KOLTEPATIL.NS balance_sheet (annual, 2025-03-31) — Accumulated Depreciation: -907700000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2025-03-31) — Accumulated Depreciation: -907700000.00
KOLTEPATIL.NS balance_sheet (annual, 2025-03-31) — Additional Paid In Capital: 3393500000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2025-03-31) — Additional Paid In Capital: 3393500000.00
KOLTEPATIL.NS balance_sheet (annual, 2025-03-31) — Allowance For Doubtful Accounts Receivable: -89000000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2025-03-31) — Allowance For Doubtful Accounts Receivable: -89000000.00
KOLTEPATIL.NS income_statement (annual, 2025-03-31) — Amortization: 6700000.00
KOLTEPATIL.NS cash_flow (annual, 2025-03-31) — Amortization Cash Flow: 6700000.00
KOLTEPATIL.NS balance_sheet (annual, 2025-03-31) — Available For Sale Securities: 1279100000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2025-03-31) — Available For Sale Securities: 1279100000.00
KOLTEPATIL.NS income_statement (annual, 2025-03-31) — Basic Average Shares: 76000000.00
KOLTEPATIL.NS income_statement (annual, 2025-03-31) — Basic EPS: 14.02
KOLTEPATIL.NS cash_flow (annual, 2025-03-31) — Beginning Cash Position: 2997600000.00
KOLTEPATIL.NS balance_sheet (annual, 2025-03-31) — Buildings And Improvements: 62600000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2025-03-31) — Buildings And Improvements: 62600000.00
KOLTEPATIL.NS cash_flow (annual, 2025-03-31) — Capital Expenditure: -574600000.00
KOLTEPATIL.NS balance_sheet (annual, 2025-03-31) — Capital Lease Obligations: 300900000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2025-03-31) — Capital Lease Obligations: 300900000.00
KOLTEPATIL.NS balance_sheet (annual, 2025-03-31) — Capital Stock: 760000000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2025-03-31) — Capital Stock: 760000000.00
KOLTEPATIL.NS balance_sheet (annual, 2025-03-31) — Cash And Cash Equivalents: 1804100000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2025-03-31) — Cash And Cash Equivalents: 1804100000.00
KOLTEPATIL.NS balance_sheet (annual, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 4105700000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 4105700000.00
KOLTEPATIL.NS cash_flow (annual, 2025-03-31) — Cash Dividends Paid: -304000000.00
KOLTEPATIL.NS balance_sheet (annual, 2025-03-31) — Cash Equivalents: 147800000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2025-03-31) — Cash Equivalents: 147800000.00
KOLTEPATIL.NS balance_sheet (annual, 2025-03-31) — Cash Financial: 1656300000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2025-03-31) — Cash Financial: 1656300000.00
KOLTEPATIL.NS cash_flow (annual, 2025-03-31) — Change In Inventory: -220600000.00
KOLTEPATIL.NS cash_flow (annual, 2025-03-31) — Change In Other Current Assets: -1227100000.00
KOLTEPATIL.NS cash_flow (annual, 2025-03-31) — Change In Other Current Liabilities: 2929200000.00
KOLTEPATIL.NS cash_flow (annual, 2025-03-31) — Change In Payable: -304900000.00
KOLTEPATIL.NS cash_flow (annual, 2025-03-31) — Change In Receivables: -67100000.00
KOLTEPATIL.NS cash_flow (annual, 2025-03-31) — Change In Working Capital: 1112200000.00
KOLTEPATIL.NS cash_flow (annual, 2025-03-31) — Changes In Cash: -1193500000.00
KOLTEPATIL.NS balance_sheet (annual, 2025-03-31) — Common Stock: 760000000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2025-03-31) — Common Stock: 760000000.00
KOLTEPATIL.NS balance_sheet (annual, 2025-03-31) — Common Stock Equity: 8301200000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2025-03-31) — Common Stock Equity: 8301200000.00
KOLTEPATIL.NS balance_sheet (annual, 2025-03-31) — Construction In Progress: 13600000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2025-03-31) — Construction In Progress: 13600000.00
KOLTEPATIL.NS income_statement (annual, 2025-03-31) — Cost Of Revenue: 12968400000.00
KOLTEPATIL.NS income_statement (quarterly, 2025-03-31) — Cost Of Revenue: 5391200000.00
KOLTEPATIL.NS balance_sheet (annual, 2025-03-31) — Current Assets: 45478900000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2025-03-31) — Current Assets: 45478900000.00
KOLTEPATIL.NS balance_sheet (annual, 2025-03-31) — Current Capital Lease Obligation: 99400000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2025-03-31) — Current Capital Lease Obligation: 99400000.00
KOLTEPATIL.NS balance_sheet (annual, 2025-03-31) — Current Debt: 11046200000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2025-03-31) — Current Debt: 11046200000.00
KOLTEPATIL.NS balance_sheet (annual, 2025-03-31) — Current Debt And Capital Lease Obligation: 11145600000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2025-03-31) — Current Debt And Capital Lease Obligation: 11145600000.00
KOLTEPATIL.NS balance_sheet (annual, 2025-03-31) — Current Liabilities: 44287700000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2025-03-31) — Current Liabilities: 44287700000.00
KOLTEPATIL.NS balance_sheet (annual, 2025-03-31) — Current Provisions: 163500000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2025-03-31) — Current Provisions: 163500000.00
KOLTEPATIL.NS cash_flow (annual, 2025-03-31) — Depreciation: 136100000.00
KOLTEPATIL.NS cash_flow (annual, 2025-03-31) — Depreciation And Amortization: 142800000.00
KOLTEPATIL.NS income_statement (annual, 2025-03-31) — Depreciation And Amortization In Income Statement: 142800000.00
KOLTEPATIL.NS income_statement (quarterly, 2025-03-31) — Depreciation And Amortization In Income Statement: 42700000.00
KOLTEPATIL.NS income_statement (annual, 2025-03-31) — Depreciation Income Statement: 136100000.00
KOLTEPATIL.NS income_statement (quarterly, 2025-03-31) — Depreciation Income Statement: 36000000.00
KOLTEPATIL.NS income_statement (annual, 2025-03-31) — Diluted Average Shares: 76200000.00
KOLTEPATIL.NS income_statement (annual, 2025-03-31) — Diluted EPS: 13.99
KOLTEPATIL.NS income_statement (annual, 2025-03-31) — Diluted NI Availto Com Stockholders: 1065600000.00
KOLTEPATIL.NS income_statement (quarterly, 2025-03-31) — Diluted NI Availto Com Stockholders: 652800000.00
KOLTEPATIL.NS balance_sheet (annual, 2025-03-31) — Dividends Payable: 1400000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2025-03-31) — Dividends Payable: 1400000.00
KOLTEPATIL.NS cash_flow (annual, 2025-03-31) — Dividends Received Cfi: 12200000.00
KOLTEPATIL.NS income_statement (annual, 2025-03-31) — EBIT: 2091400000.00
KOLTEPATIL.NS income_statement (quarterly, 2025-03-31) — EBIT: 1036700000.00
KOLTEPATIL.NS income_statement (annual, 2025-03-31) — EBITDA: 2234200000.00
KOLTEPATIL.NS income_statement (quarterly, 2025-03-31) — EBITDA: 1079400000.00
KOLTEPATIL.NS cash_flow (annual, 2025-03-31) — End Cash Position: 1804100000.00
KOLTEPATIL.NS balance_sheet (annual, 2025-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 1200000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2025-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 1200000.00
KOLTEPATIL.NS cash_flow (annual, 2025-03-31) — Financing Cash Flow: -1604200000.00
KOLTEPATIL.NS balance_sheet (annual, 2025-03-31) — Finished Goods: 35581000000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2025-03-31) — Finished Goods: 35581000000.00
KOLTEPATIL.NS cash_flow (annual, 2025-03-31) — Free Cash Flow: 2244500000.00
KOLTEPATIL.NS cash_flow (annual, 2025-03-31) — Gain Loss On Investment Securities: -58300000.00
KOLTEPATIL.NS cash_flow (annual, 2025-03-31) — Gain Loss On Sale Of PPE: -1100000.00
KOLTEPATIL.NS income_statement (annual, 2025-03-31) — General And Administrative Expense: 233600000.00
KOLTEPATIL.NS balance_sheet (annual, 2025-03-31) — Goodwill: 0.00
KOLTEPATIL.NS balance_sheet (quarterly, 2025-03-31) — Goodwill: 0.00
KOLTEPATIL.NS balance_sheet (annual, 2025-03-31) — Goodwill And Other Intangible Assets: 5600000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2025-03-31) — Goodwill And Other Intangible Assets: 5600000.00
KOLTEPATIL.NS balance_sheet (annual, 2025-03-31) — Gross Accounts Receivable: 710300000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2025-03-31) — Gross Accounts Receivable: 710300000.00
KOLTEPATIL.NS balance_sheet (annual, 2025-03-31) — Gross PPE: 2423400000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2025-03-31) — Gross PPE: 2423400000.00
KOLTEPATIL.NS income_statement (annual, 2025-03-31) — Gross Profit: 4205400000.00
KOLTEPATIL.NS income_statement (quarterly, 2025-03-31) — Gross Profit: 1795500000.00
KOLTEPATIL.NS income_statement (annual, 2025-03-31) — Interest Expense: 379700000.00
KOLTEPATIL.NS income_statement (quarterly, 2025-03-31) — Interest Expense: 24300000.00
KOLTEPATIL.NS income_statement (annual, 2025-03-31) — Interest Expense Non Operating: 379700000.00
KOLTEPATIL.NS income_statement (quarterly, 2025-03-31) — Interest Expense Non Operating: 24300000.00
KOLTEPATIL.NS income_statement (annual, 2025-03-31) — Interest Income: 156700000.00
KOLTEPATIL.NS income_statement (annual, 2025-03-31) — Interest Income Non Operating: 156700000.00
KOLTEPATIL.NS cash_flow (annual, 2025-03-31) — Interest Paid Cff: -1062600000.00
KOLTEPATIL.NS cash_flow (annual, 2025-03-31) — Interest Received Cfi: 135900000.00
KOLTEPATIL.NS balance_sheet (annual, 2025-03-31) — Inventory: 36107000000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2025-03-31) — Inventory: 36107000000.00
KOLTEPATIL.NS balance_sheet (annual, 2025-03-31) — Invested Capital: 19390100000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2025-03-31) — Invested Capital: 19390100000.00
KOLTEPATIL.NS cash_flow (annual, 2025-03-31) — Investing Cash Flow: -2408400000.00
KOLTEPATIL.NS balance_sheet (annual, 2025-03-31) — Investment Properties: 169000000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2025-03-31) — Investment Properties: 169000000.00
KOLTEPATIL.NS balance_sheet (annual, 2025-03-31) — Investmentin Financial Assets: 1200000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2025-03-31) — Investmentin Financial Assets: 1200000.00
KOLTEPATIL.NS balance_sheet (annual, 2025-03-31) — Investmentsin Associatesat Cost: 184400000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2025-03-31) — Investmentsin Associatesat Cost: 184400000.00
KOLTEPATIL.NS balance_sheet (annual, 2025-03-31) — Investmentsin Joint Venturesat Cost: 8600000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2025-03-31) — Investmentsin Joint Venturesat Cost: 8600000.00
KOLTEPATIL.NS cash_flow (annual, 2025-03-31) — Issuance Of Debt: 4139100000.00
KOLTEPATIL.NS balance_sheet (annual, 2025-03-31) — Land And Improvements: 55500000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2025-03-31) — Land And Improvements: 55500000.00
KOLTEPATIL.NS balance_sheet (annual, 2025-03-31) — Long Term Capital Lease Obligation: 201500000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2025-03-31) — Long Term Capital Lease Obligation: 201500000.00
KOLTEPATIL.NS balance_sheet (annual, 2025-03-31) — Long Term Debt: 42700000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2025-03-31) — Long Term Debt: 42700000.00
KOLTEPATIL.NS balance_sheet (annual, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 244200000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 244200000.00
KOLTEPATIL.NS cash_flow (annual, 2025-03-31) — Long Term Debt Issuance: 4139100000.00
KOLTEPATIL.NS cash_flow (annual, 2025-03-31) — Long Term Debt Payments: -4295800000.00
KOLTEPATIL.NS balance_sheet (annual, 2025-03-31) — Long Term Equity Investment: 193000000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2025-03-31) — Long Term Equity Investment: 193000000.00
KOLTEPATIL.NS balance_sheet (annual, 2025-03-31) — Long Term Provisions: 129100000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2025-03-31) — Long Term Provisions: 129100000.00
KOLTEPATIL.NS balance_sheet (annual, 2025-03-31) — Machinery Furniture Equipment: 2070800000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2025-03-31) — Machinery Furniture Equipment: 2070800000.00
KOLTEPATIL.NS balance_sheet (annual, 2025-03-31) — Minority Interest: 72000000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2025-03-31) — Minority Interest: 72000000.00
KOLTEPATIL.NS income_statement (annual, 2025-03-31) — Minority Interests: -27700000.00
KOLTEPATIL.NS income_statement (quarterly, 2025-03-31) — Minority Interests: -10000000.00
KOLTEPATIL.NS cash_flow (annual, 2025-03-31) — Net Business Purchase And Sale: -94200000.00
KOLTEPATIL.NS balance_sheet (annual, 2025-03-31) — Net Debt: 9284800000.00
KOLTEPATIL.NS balance_sheet (quarterly, 2025-03-31) — Net Debt: 9284800000.00
KOLTEPATIL.NS income_statement (annual, 2025-03-31) — Net Income: 1065600000.00
KOLTEPATIL.NS income_statement (quarterly, 2025-03-31) — Net Income: 652800000.00
KOLTEPATIL.NS income_statement (annual, 2025-03-31) — Net Income Common Stockholders: 1065600000.00
KOLTEPATIL.NS income_statement (quarterly, 2025-03-31) — Net Income Common Stockholders: 652800000.00
KOLTEPATIL.NS income_statement (annual, 2025-03-31) — Net Income Continuous Operations: 1093300000.00
KOLTEPATIL.NS income_statement (quarterly, 2025-03-31) — Net Income Continuous Operations: 662800000.00
KOLTEPATIL.NS income_statement (annual, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 1065600000.00
KOLTEPATIL.NS income_statement (quarterly, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 652800000.00
KOLTEPATIL.NS income_statement (annual, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: 1065600000.00